Interactive Rehabilitation for Adults With Unilateral Vestibular Weakness

November 23, 2022 updated by: Eytan A. David

Efficacy of Vestibular Rehabilitation Using Computerized Dynamic Posturography With Virtual Reality for Stable Unilateral Vestibular Weakness

People that have difficulty with balance, such as those with damage to their inner ear, have a higher risk of falling, which may lead to anxiety and reduced quality of life. Some individuals that have lost part of their sense of balance can learn to compensate using information from their vision, their sense of where their limbs are in space, and from other balance organs that are still intact. Our study aims to determine if virtual reality used together with information from footplate sensors can be used to train people with balance problems to compensate for their inner ear deficits.

Study Overview

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • North Vancouver, British Columbia, Canada, V7M 2H5
        • Dr. EA David MD FRCSC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult Age 18-80
  • Unilateral vestibular weakness confirmed one or more of:

    • Videonystagmography
    • VEMP
  • Or unilateral vestibular weakness idiopathic, not yet diagnosed (NYD)
  • Persistent imbalance following diagnosis of resolved benign paroxysmal positional vertigo (BPPV)
  • Symptomatic
  • Long-standing/persistent symptoms greater than one year

Exclusion Criteria:

  • Orthopedic deficit (eg. lower body joint dysfunction or lower joint replacement)
  • Neurological deficit or proprioception deficit
  • Diabetes
  • Poor vision or blindness
  • Fluctuating vestibular symptoms, or condition known to fluctuate eg. Menière's disease, perilymphatic fistula (PLF) or superior canal deshicsence (SDCS)
  • Active benign paroxysmal positional vertigo (BPPV)
  • Undergoing treatment which may affect balance or ability to stand
  • Cognitive impairment that prevents understanding and responding to instructions required to complete the study
  • Inability to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vestibular rehabilitation with dynamic posturography
12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
Rehabilitation exercises guided by an interactive display and measured by a footplate sensor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sensory Organization Test (SOT) Composite Score (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks

Change in composite score of Sensory Organization Test (SOT) (Scores from 0-100; higher scores indicate better function); Lower scores indicate larger amount of sway

Calculated as a composite of the 6 individual conditions of the SOT:

  1. Eyes open on firm surface
  2. Eyes closed on firm surface
  3. Eyes open with sway referenced visual
  4. Eyes open on sway referenced support surface
  5. Eyes close on sway referenced support surfrace
  6. Eyes open on sway referenced support surface and visual
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Dizziness Handicap Inventory Score (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Dizziness Handicap Inventory (DHI); scale from 0-100; higher scores indicate greater disability; 16-34 Points (mild handicap), 36-52 Points (moderate handicap), 54+ Points (severe handicap)
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Activities-specific Balance Confidence Scale Score (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Activities-specific Balance Confidence (ABC) score; (Scores from 0-100; higher scores indicate greater confidence in performing activities of daily living)
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Fall Efficacy Scale-International (FES-I) (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Fall Efficacy Scale-International (FES-I); possible scores 16-64, higher score indicates greater perceived fall risk
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Limits of Stability Area (Area After Retraining Minus Area at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks

Change in endpoint excursion and maximum excursion functional stability region area, calculated from Limits of Stability (LOS) score Higher score indicates an ability to volitionally lean to larger angles. 100% of theoretical maximum in all directions would give an area of 28284.

LOS excursion scores were calculated by the instrument software, from which we calculated the area of the endpoint excursion functional stability region (the sum of areas between adjacent Endpoint Excursion limits) and the area of the maximum excursion functional stability region (the sum of areas between adjacent Maximum Excursion limits) using published methods (Alvarez-Otero R, Perez-Fernandez N. The limits of stability in patients with unilateral vestibulopathy. Acta Oto-laryngol. 2017;137(10):1-6. doi:10.1080/00016489.2017.1339326)

Through study completion, 12 rehabilitation sessions, an average of 7 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sensory Organization Test Scores for Conditions 1 to 6 (Scores After Retraining Minus Scores at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks

Change in mean Sensory Organization Test Scores for conditions 1 through 6; (Scores from 0-100; higher scores indicate better function)

The 6 conditions are:

  1. Eyes open on firm surface
  2. Eyes closed on firm surface
  3. Eyes open with sway referenced visual
  4. Eyes open on sway referenced support surface
  5. Eyes close on sway referenced support surfrace
  6. Eyes open on sway referenced support surface and visual
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Sensory Organization Test Vestibular Contribution (Ratio After Retraining Minus Ratio at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in mean value of Sensory Organization Test condition 5/mean value of SOT conditions 1; measured as a ratio, higher scores indicate a greater vestibular contribution to balance deficit
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Limits of Stability Directional Control Component (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Limits of Stability test mean value of directional control of limits of stability; (Scores from 0-100; higher scores indicate better function)
Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Change in Endpoint and Maximum Excursion Values From Limits of Stability Test (Score After Retraining Minus Score at Baseline)
Time Frame: Through study completion, 12 rehabilitation sessions, an average of 7 weeks
Limits of Stability test mean endpoint excursion value and maximum excursion point; (Scores from 0-100; higher scores indicate better function)
Through study completion, 12 rehabilitation sessions, an average of 7 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to Rehabilitation Protocol
Time Frame: Through study completion, maximum of 12 weeks
Percentage of subjects that complete 12 sessions
Through study completion, maximum of 12 weeks
Missed Sessions
Time Frame: Through study completion, maximum of 12 weeks
Mean number of missed and rescheduled rehabilitation sessions
Through study completion, maximum of 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Eytan David, MD, University of British Columbia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 10, 2021

Primary Completion (Actual)

October 31, 2021

Study Completion (Actual)

October 31, 2021

Study Registration Dates

First Submitted

April 27, 2021

First Submitted That Met QC Criteria

April 30, 2021

First Posted (Actual)

May 6, 2021

Study Record Updates

Last Update Posted (Estimate)

December 20, 2022

Last Update Submitted That Met QC Criteria

November 23, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • H20-04045

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

No individual participant data will be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dizziness

Clinical Trials on Vestibular rehabilitation with dynamic posturography

3
Subscribe